This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sequenom's Management Presents At Bank Of America Merrill Lynch 2012 Healthcare Conference (Transcript)

Sequenom Inc. (SQNM)

Bank of America Merrill Lynch 2012 Healthcare Conference Call

May 15, 2012 4:00 p.m. ET

Executives

Ron Lindsay, Ph.D. - Director and Executive Vice President, Research & Development

William Welsh - Senior Vice President, Diagnostics

Dirk van de Boom, Ph.D. - Senior Vice President, Research & Development

Analysts

Derik de Bruin - Bank of America Merrill Lynch

Presentation

Welcome to the afternoon session of the 2012 Bank of America Merrill Lynch Healthcare Conference. I’m Derik de Bruin, the life sciences, tools and diagnostics analyst and our first company up this afternoon is going to be Sequenom. Here today from Sequenom we have Ron Lindsay, Director and Executive VP of R&D. We also have William Welsh, Senior Vice President, Diagnostics, and Dirk van de Boom, Senior VP of R&D, with us here today and there’ll be a brief presentation and then we’ll open it up for questions and answers after that.

With that, thank you and look forward to hearing it.

Ron Lindsay

Thanks. Okay. All right. Thank you, Derrick, and good afternoon, everyone, and welcome to the Sequenom presentation and I’d like thank B of A for the opportunity to be here for the first time and, in keeping with the recommendation, we’ll probably show fewer slides than usual, but, hopefully, we can update you on some key points.

For the last two or three years the senior leadership team and Sequenom has been sometimes accused, rightly or wrongly, of being very conservative. This is the bags that we don’t to give up in the near future, but I think its fair to say six months into launch of a very important product, we’re actually pretty mildly excited, I’d have to say. I think we share with you some of the updates on that and we’ll have time for some Q&A at the end.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,539.78 -114.99 -0.69%
S&P 500 1,983.39 -4.27 -0.21%
NASDAQ 4,816.3320 +3.6240 0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs